SynVaccine
Developer of a platform for computational design and manufacture of synthetic viruses for vaccines, gene therapy and oncolytic immunotherapy. Uses a proprietary design-build-validate workflow that combines bioinformatic rules derived from viral evolution, selection of gene-editing and synthesis tools, and iterative in vitro and animal validation to produce tailored viral products for human and veterinary applications.
Industries
Nr. of Employees
small (1-50)
Patents
Attenuated virus mutated at sites of evolutionarily conserved RNA structure
US-11795440-B2
View DetailsAttenuated virus mutated at sites of evolutionarily conserved RNA structure
US-11111481-B2
View Details
Attenuated virus mutated at sites of evolutionarily conserved RNA structure
US-11795440-B2
View DetailsAttenuated virus mutated at sites of evolutionarily conserved RNA structure
US-11111481-B2
View DetailsProducts
Platform-derived viral vaccine candidates
Viral vaccine candidates developed via de-novo computational design and iterative validation; first-line programs target several human pathogens and animal health targets.
Oncolytic virus candidates for cancer immunotherapy
Engineered oncolytic viruses designed for tumor-selective replication and immune stimulation with tuned replication and transgene expression.
Proprietary platform for rational virus design and manufacture
An integrated platform (computational design, construction and validation) enabling rational creation of viral-based products.
Platform-derived viral vaccine candidates
Viral vaccine candidates developed via de-novo computational design and iterative validation; first-line programs target several human pathogens and animal health targets.
Oncolytic virus candidates for cancer immunotherapy
Engineered oncolytic viruses designed for tumor-selective replication and immune stimulation with tuned replication and transgene expression.
Proprietary platform for rational virus design and manufacture
An integrated platform (computational design, construction and validation) enabling rational creation of viral-based products.
Services
Design of de-novo viral genomes and sequence engineering to achieve specified expression and fitness properties.
Integrated design-build-validate development of vaccine and viral therapeutic candidates including in vitro and animal validation with iterative feedback to design.
Collaborative programs aimed at rapid, cost-efficient development of vaccines for livestock and other animals using the platform.
Design of de-novo viral genomes and sequence engineering to achieve specified expression and fitness properties.
Integrated design-build-validate development of vaccine and viral therapeutic candidates including in vitro and animal validation with iterative feedback to design.
Collaborative programs aimed at rapid, cost-efficient development of vaccines for livestock and other animals using the platform.
Expertise Areas
- Synthetic virology
- Viral genome engineering
- Vaccine development (human and veterinary)
- Oncolytic immunotherapy development
Key Technologies
- Computational viral genome design
- CAD/CAM for virus fabrication
- De-novo virus synthesis
- Gene editing and DNA synthesis
News & Updates
Peer-reviewed publication demonstrating computational design and tracking of synthetic viral variants and relations between silent genomic information and viral fitness.
Member of the ARDAT consortium aimed at accelerating R&D for advanced therapy medicinal products; contributes computational synthetic biology tools for viral engineering and AAV/transgene design.
Awarded the European Commission Seal of Excellence following an SME instrument phase 2 submission.
Recipient of the European Commission Horizon 2020 SME Instrument Phase 1 grant.
Raised seed funding reported in press coverage.
Finalist in multiple innovation and startup competitions (e.g., Animal Health showcases, Falling Walls Venture).
Peer-reviewed publication demonstrating computational design and tracking of synthetic viral variants and relations between silent genomic information and viral fitness.
Member of the ARDAT consortium aimed at accelerating R&D for advanced therapy medicinal products; contributes computational synthetic biology tools for viral engineering and AAV/transgene design.
Awarded the European Commission Seal of Excellence following an SME instrument phase 2 submission.
Recipient of the European Commission Horizon 2020 SME Instrument Phase 1 grant.
Raised seed funding reported in press coverage.
Finalist in multiple innovation and startup competitions (e.g., Animal Health showcases, Falling Walls Venture).